{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:06:02Z","timestamp":1781625962158,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The clinical feasibility and efficacy of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in patients with anemia in chronic kidney disease (CKD) remain uncertain. Red blood cell distribution width (RDW) may serve as a potential predictor for responsiveness to HIF-PH inhibitor therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consecutive patients receiving HIF-PH inhibitors for anemia in CKD over three months were included. The predictive value of baseline RDW for the improvement in anemia in CKD, defined by the increase in hemoglobin levels to 10.0\u00a0g\/dL or higher at within the first three months after initiation of therapy and the maintenance of that level thereafter, was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 106 patients were enrolled (median age 79 years; 57 males; 75 patients with heart failure; median estimated glomerular filtration rate 25.0 mL\/min\/1.73\u00a0m\u00b2; median hemoglobin level 9.3\u00a0g\/dL). Among these, 84 patients met the primary outcome criteria. Baseline RDW-coefficient of variation (CV) ranged from 11.8% to 22.4%, with a median of 14.0%. Baseline RDW-CV independently predicted the primary outcome, with an odds ratio of 2.43 (95% confidence interval: 1.42\u20134.14,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). The optimal cutoff value for predicting the primary outcome was identified as 13.7% (sensitivity 0.67, specificity 0.86). In addition, baseline RDW-CV levels were not significantly associated with overall and renal-related prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline RDW-CV independently predicts the therapeutic efficacy of mid-term HIF-PH inhibitor treatment for anemia in CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-025-04675-2","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:47:24Z","timestamp":1764996444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of red blood cell distribution width on response to HIF-PH inhibitor in improving anemia and clinical outcomes in patients with chronic kidney disease"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5980-1021","authenticated-orcid":false,"given":"Sayaka","family":"Murai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0164-8290","authenticated-orcid":false,"given":"Kota","family":"Kakeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-7637","authenticated-orcid":false,"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5912-1870","authenticated-orcid":false,"given":"Tsutomu","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-4356","authenticated-orcid":false,"given":"Hidenori","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0009-8477","authenticated-orcid":false,"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"4675_CR1","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"Lin\u2008HY Babitt\u2008JL","year":"2012","unstructured":"Babitt\u2008JL Lin\u2008HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631\u20134.","journal-title":"J Am Soc Nephrol"},{"key":"4675_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/ckj\/sfac240","volume":"16","author":"CP Kovesdy","year":"2023","unstructured":"Kovesdy CP, Davis JR, Duling I, Little DJ. Prevalence of anemia in adults with chronic kidney disease in a representative sample of the united States population: analysis of the 1999\u20132018 National health and nutrition examination survey. Clin Kidney J. 2023;16:303\u201311.","journal-title":"Clin Kidney J"},{"key":"4675_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11255-006-0064-8","volume":"38","author":"DS Silverberg","year":"2006","unstructured":"Silverberg DS, Wexler D, Iaina A, Steinbruch S, Wollman Y, Schwartz D. Anemia, chronic renal disease and congestive heart failure\u2014the cardio renal anemia syndrome: the need for Cooperation between cardiologists and nephrologists. Int Urol Nephrol. 2006;38:295\u2013310.","journal-title":"Int Urol Nephrol"},{"key":"4675_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1440-1797.2007.00810.x","volume":"12","author":"DW Johnson","year":"2007","unstructured":"Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrol (Carlton Vic). 2007;12:321\u201330.","journal-title":"Nephrol (Carlton Vic)"},{"key":"4675_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/ndt\/17.suppl_1.53","volume":"17","author":"D Richardson","year":"2002","unstructured":"Richardson D. Clinical factors influencing sensitivity and response to Epoetin. Nephrol Dial Transpl. 2002;17:53\u20139.","journal-title":"Nephrol Dial Transpl"},{"key":"4675_CR6","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1126\/science.1104742","volume":"306","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to Ferroportin and inducing its internalization. Science. 2004;306:2090\u20133.","journal-title":"Science"},{"key":"4675_CR7","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with Epoetin Alfa in chronic kidney disease. N Engl J Med. 2006;355:2085\u201398.","journal-title":"N Engl J Med"},{"key":"4675_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, et al. Roxadustat for anemia in patients with kidney disease not receiving Dialysis. N Engl J Med. 2019;381:1001\u201310.","journal-title":"N Engl J Med"},{"key":"4675_CR9","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","volume":"384","author":"GM Chertow","year":"2021","unstructured":"Chertow GM, Pergola PE, Farag YMK, Agarwal R, Arnold S, Bako G, et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med. 2021;384:1589\u2013600.","journal-title":"N Engl J Med"},{"key":"4675_CR10","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","volume":"385","author":"AK Singh","year":"2021","unstructured":"Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, et al. Daprodustat for the treatment of anemia in patients not undergoing Dialysis. N Engl J Med. 2021;385:2313\u201324.","journal-title":"N Engl J Med"},{"key":"4675_CR11","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.ekir.2021.04.037","volume":"6","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Nangaku M, Yamaguchi T, Koretomo R, Maeda K, Miyazawa Y, et al. A phase 3 study of Enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study. Kidney Int Rep. 2021;6:1840\u20139.","journal-title":"Kidney Int Rep"},{"key":"4675_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10157-023-02353-x","volume":"27","author":"H Yamamoto","year":"2023","unstructured":"Yamamoto H, Yamada T, Miyazaki K, Yamashita T, Kato T, Ohara K, et al. Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials. Clin Exp Nephrol. 2023;27:651\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"4675_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","volume":"11","author":"VH Haase","year":"2021","unstructured":"Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl. 2021;11:8\u201325.","journal-title":"Kidney Int Suppl"},{"key":"4675_CR14","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1172\/JCI38499","volume":"119","author":"M Mastrogiannaki","year":"2009","unstructured":"Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. HIF-2\u03b1, but not HIF-1\u03b1, promotes iron absorption in mice. J Clin Invest. 2009;119:1159\u201366.","journal-title":"J Clin Invest"},{"key":"4675_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.clnu.2024.01.001","volume":"43","author":"E Haenggi","year":"2024","unstructured":"Haenggi E, Kaegi-Braun N, Wunderle C, Tribolet P, Mueller B, Stanga Z, et al. Red blood cell distribution width (RDW) - A new nutritional biomarker to assess nutritional risk and response to nutritional therapy? Clin Nutr. 2024;43:575\u201385.","journal-title":"Clin Nutr"},{"key":"4675_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/10408363.2014.992064","volume":"52","author":"GL Salvagno","year":"2015","unstructured":"Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: a simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52:86\u2013105.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"4675_CR17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.5603\/CJ.a2018.0103","volume":"27","author":"R Targo\u0144ski","year":"2020","unstructured":"Targo\u0144ski R, Sadowski J, Starek-Stelmaszczyk M, Targo\u0144ski R, Rynkiewicz A. Prognostic significance of red cell distribution width and its relation to increased pulmonary pressure and inflammation in acute heart failure. Cardiol J. 2020;27:394\u2013403.","journal-title":"Cardiol J"},{"key":"4675_CR18","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.ejim.2012.11.017","volume":"24","author":"B Afsar","year":"2013","unstructured":"Afsar B, Saglam M, Yuceturk C, Agca E. The relationship between red cell distribution width with erythropoietin resistance in iron replete Hemodialysis patients. Eur J Intern Med. 2013;24:e25\u20139.","journal-title":"Eur J Intern Med"},{"key":"4675_CR19","doi-asserted-by":"crossref","unstructured":"Tonelli M, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M et al. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation. 2008; 117: 163-8.","DOI":"10.1161\/CIRCULATIONAHA.107.727545"},{"key":"4675_CR20","unstructured":"Astellas Pharma Inc. Interview form of Roxadustat. 2025. https:\/\/www.gifu-upharm.jp\/di\/mdoc\/iform\/2g\/i1139232505.pdf. Accessed 2 November 2025."},{"key":"4675_CR21","unstructured":"Mitsubishi Tanabe Pharma Corporation. Interview form of Vadadustat. 2023. https:\/\/www.gifu-upharm.jp\/di\/mdoc\/iform\/2g\/i1646682303.pdf. Accessed 2 November 2025."},{"key":"4675_CR22","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1515\/cclm-2014-0585","volume":"52","author":"G Lippi","year":"2014","unstructured":"Lippi G, Plebani M. Red blood cell distribution width (RDW) and human pathology. One size fits all. Clin Chem Lab Med. 2014;52:1247\u20139.","journal-title":"Clin Chem Lab Med"},{"key":"4675_CR23","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"4675_CR24","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/s10157-024-02511-9","volume":"28","author":"E Imai","year":"2024","unstructured":"Imai E, Imai A. The comparison of four hypoxia-inducible factor Prolyl hydroxylase inhibitors on drug potency and cost for treatment in patients with renal anemia. Clin Exp Nephrol. 2024;28:1090\u20136.","journal-title":"Clin Exp Nephrol"},{"key":"4675_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12882-024-03877-4","volume":"25","author":"K Odajima","year":"2024","unstructured":"Odajima K, Arai S, Kido R, Anzai H, Gojo M, Taira S, et al. Erythrocyte indices and response to hypoxia-inducible factor Prolyl hydroxylase inhibitors in chronic kidney disease patients with renal anemia: a retrospective study. BMC Nephrol. 2024;25:423.","journal-title":"BMC Nephrol"},{"key":"4675_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmaf005","author":"T Murata","year":"2025","unstructured":"Murata T, Fukuoka T, Fujii T, Yujiri T. Hepcidin values can help predict the responsiveness of Roxadustat for treating anemia in patients with chronic kidney disease. Lab Med. 2025. https:\/\/doi.org\/10.1093\/labmed\/lmaf005.","journal-title":"Lab Med"},{"key":"4675_CR27","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/eurjhf\/hfr127","volume":"13","author":"Y Born\u00e9","year":"2011","unstructured":"Born\u00e9 Y, Smith JG, Melander O, Hedblad B, Engstr\u00f6m G. Red cell distribution width and risk for first hospitalization due to heart failure: a population-based cohort study. Eur J Heart Fail. 2011;13:1355\u201361.","journal-title":"Eur J Heart Fail"},{"key":"4675_CR28","first-page":"177","volume":"100","author":"A Das Gupta","year":"1994","unstructured":"Das Gupta A, Hegde C, Mistri R. Red cell distribution width as a measure of severity of iron deficiency in iron deficiency anaemia. Indian J Med Res. 1994;100:177\u201383.","journal-title":"Indian J Med Res"},{"key":"4675_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/ndt\/17.suppl_11.39","volume":"17","author":"IC Macdougall","year":"2002","unstructured":"Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transpl. 2002;17:39\u201343.","journal-title":"Nephrol Dial Transpl"},{"key":"4675_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1001\/jamacardio.2016.1161","volume":"1","author":"JG Cleland","year":"2016","unstructured":"Cleland JG, Zhang J, Pellicori P, Dicken B, Dierckx R, Shoaib A, et al. Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. JAMA Cardiol. 2016;1:539\u201347.","journal-title":"JAMA Cardiol"},{"key":"4675_CR31","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1161\/CIRCULATIONAHA.105.577577","volume":"113","author":"AS Go","year":"2006","unstructured":"Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the anemia in chronic heart failure: outcomes and resource utilization (ANCHOR) study. Circulation. 2006;113:2713\u201323.","journal-title":"Circulation"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04675-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04675-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04675-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:05:27Z","timestamp":1781622327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04675-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4675"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04675-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Institutional Ethics Committee (approval number R2024206, dated February 14, 2025). Given the retrospective design and the adoption of an opt-out approach, the requirement for informed consent was waived. The study adhered strictly to the principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}